Life Sciences

For the last decade, life sciences companies have faced many challenges: expiry of patents, price competition from generic producers, a rising cost base, low productivity in research and development, ongoing talent shortages, and challenges to their corporate reputations, to name a few. In such a daunting environment, it is clear that companies may need to transform in order to remain high-value-added innovators — and avoid becoming lower-margin suppliers.

Our industry specialists from across Deloitte provide an extensive depth of knowledge on the range of current issues experienced by the pharmaceuticals, biotechnology and medical device industries. 

For case studies or examples of specific issues tackled and benefits gained please contact our team.

More Hot topics

  • Positioning for prosperity? Catching the next wave
    The Deloitte Growth 25 (DG25), identifies reasons to be optimistic about growth in Australia. Download the latest Building the Lucky Country report.
    Deloitte report, March 2014 | 102 pages
  • Adjusting to the new world of risk management
    Surveys 192 senior TMT, Life Sciences & Consumer/Industrial Products company executives on current risk management issues & practice.
    Deloitte/Forbes Insights Executive Survey, May 2012 I 20 pages
  • Investment in new technologies: CEO survey findings
    Covers past & projected use of R&D incentives & investment in new technologies in the manufacturing, construction & services sectors.
    Australian Industry Group/Deloitte CEO Survey, January 2012 | 26 pages
  • Chinese outbound M&A: Life Sciences & Health Care
    Five year review of greater China LSHC (and other sector) M&A activity plus future deal expectations drawing from mergermarket data.
    2011 Greater China M&A Spotlight, October 2011 | 72 pages
  • Key Findings in Global Consumer Survey
    This survey offers several important considerations for pharmaceutical, biotechnology, and medical device companies.
    Survey Report, June 2011 | 4 pages